/RYZB

RYZB Stock - RayzeBio, Inc. Common Stock

Q: What is the analyst price target for RYZB?

Analyst price target information is not currently available for RYZB.

Q: What is RYZB's market cap?

Market capitalization information is not currently available for RYZB.

Healthcare|Biotechnology|NASDAQ

$62.49+0.02%

+$0.01 (+0.02%) • Feb 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $68.74

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RYZB

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.79

52W High$62.51

52W Low$17.95

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A
Operating Income	$-72,120,000	$-39,379,000	$-6,921,000
Net Income	$-68,600,000	$-29,444,000	$-6,916,000
Net Margin	N/A	N/A	N/A
EPS	$-1.75	$-0.73	$-0.17

Company Overview

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.

Earnings History & Surprises

RYZB

Beat Rate

Last 1 quarters

Avg Surprise

-82.6%

EPS vs Estimate

Beats / Misses

0/1

Last 12 quarters

Latest EPS

$-1.26

Q4 2023

EPS Surprise History

Q3 22

No data

Q4 22

No data

Q4 23

-82.6%

$-1.26vs$-0.69

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Mar 4, 2024	$-0.38	—	—	—
Q4 2023	Nov 13, 2023	$-0.69	$-1.26	-82.6%	✗ MISS
Q4 2022	Dec 31, 2022	—	$-0.44	—	—
Q3 2022	Sep 30, 2022	—	$-0.51	—	—

Frequently Asked Questions about RYZB

What is RYZB's current stock price?

RayzeBio, Inc. Common Stock (RYZB) is currently trading at $62.49 per share. The stock has moved +0.02% today.

What is the analyst price target for RYZB?

No analyst price targets are currently available for this stock.

What sector is RayzeBio, Inc. Common Stock in?

RayzeBio, Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is RYZB's market cap?

RayzeBio, Inc. Common Stock has a market capitalization of $3.75 billion, making it a mid-cap company.

Does RYZB pay dividends?

No, RayzeBio, Inc. Common Stock does not currently pay a dividend to shareholders.